SCHEDULE 13G/A: Major Shareholders Reaffirm Significant Stake in PolyPid Ltd., Including Warrants

A group of investors, including Rodney Hodges and affiliated entities, have filed an amended Schedule 13G, reaffirming their collective beneficial ownership of up to 19.9% of PolyPid Ltd.'s Ordinary Shares, including exercisable warrants.

Summary

• Rodney Hodges and a group of affiliated entities (POD Sarl, Geneva Holding Company (GHC) SA, Geneva Trust Company (GTC) SA, Centaurus Investments Limited, and Xenia Venture Capital Limited) have filed an amended Schedule 13G.
• The filing indicates their collective beneficial ownership of PolyPid Ltd. Ordinary Shares as of December 31, 2024.
• Rodney Hodges, POD Sarl, GHC SA, and GTC SA each beneficially own 2,242,767 Ordinary Shares, representing 19.9% of the class.
• Centaurus Investments Limited beneficially owns 2,210,717 Ordinary Shares, representing 19.6% of the class.
• Xenia Venture Capital Limited beneficially owns 1,711,792 Ordinary Shares, representing 15.5% of the class.
• The reported beneficial ownership includes 860,764 warrants held by Xenia Venture Capital Limited and 274,471 warrants held by Oriella Limited, all exercisable within 60 days of February 14, 2025.
• The percentages are calculated based on 10,190,904 Ordinary Shares outstanding as of January 17, 2025, as reported in PolyPid's Form F-3 filed on January 21, 2025.
• The filing states that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership, as required by SEC regulations. It does not contain positive or negative performance indicators, nor does it express sentiment regarding the company's prospects.

Future Outlook

The document is a factual disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Management Comments

• The document does not contain direct quotes or paraphrased statements from PolyPid Ltd.'s management. It includes a certification from Rodney Hodges and other signatories stating that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Industry Context

This Schedule 13G filing is a routine disclosure of significant beneficial ownership, common in the financial industry for transparency. It indicates a continued substantial stake by a group of investors in PolyPid Ltd., which is typical for companies with a concentrated shareholder base, particularly those that may have gone through private funding rounds or have long-term strategic investors.

Comparison to Industry Standards

• This document is a standard regulatory filing (Schedule 13G) for disclosing beneficial ownership exceeding 5%. Its content is purely factual regarding shareholdings and does not provide financial or operational results that would allow for direct comparison to industry-specific performance benchmarks or competitor companies/projects.
• The beneficial ownership percentages (ranging from 15.5% to 19.9%) are significant, indicating a concentrated ownership structure, which is not uncommon for smaller or development-stage biotechnology companies like PolyPid Ltd. where venture capital or strategic investors hold substantial stakes.
• No specific comparable companies or projects are mentioned in the filing.

Related Party Transactions

• The filing details a complex ownership structure where Rodney Hodges controls POD Sarl, which controls Geneva Holding Company (GHC) SA, which in turn controls Geneva Trust Company (GTC) SA. GTC SA acts as trustee for VT Two Trust, which holds Centaurus Investments Limited, the parent of Xenia Venture Capital Limited. This indicates a group of related entities acting in concert regarding their beneficial ownership of PolyPid Ltd. shares.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding significant beneficial ownership, which can influence perceptions of control and stability. The inclusion of warrants indicates potential future dilution if exercised, but also potential capital inflow to the company if the warrants are exercised directly with the company (though this filing doesn't specify if they are company-issued or secondary market).
• Company Management: Awareness of a significant, coordinated shareholder group may influence strategic decisions, though the filing explicitly states the shares are not held for the purpose of changing or influencing control.

Next Steps

• The document does not explicitly mention future actions, events, or milestones for PolyPid Ltd. or the reporting persons, beyond the exercisability of warrants within 60 days of February 14, 2025.

Key Dates

Keywords

PolyPid Ltd., Ordinary Shares, Schedule 13G, Beneficial Ownership, SEC Filing, Warrants, Institutional Investor, Shareholder, Rodney Hodges, Xenia Venture Capital, Centaurus Investments, Geneva Holding Company, Geneva Trust Company, POD Sarl